Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
US10017576B2 · kind B2 · utility
0Cited by
4References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 10, 2016 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Mar 24, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.